MA41757A - Transplantation ciblée de mitochondries dans des hépatocytes - Google Patents

Transplantation ciblée de mitochondries dans des hépatocytes

Info

Publication number
MA41757A
MA41757A MA041757A MA41757A MA41757A MA 41757 A MA41757 A MA 41757A MA 041757 A MA041757 A MA 041757A MA 41757 A MA41757 A MA 41757A MA 41757 A MA41757 A MA 41757A
Authority
MA
Morocco
Prior art keywords
mitochondria
hepatocytes
transplantation
targeted
targeted transplantation
Prior art date
Application number
MA041757A
Other languages
English (en)
Inventor
Nidhi Gupta
Catherine H Wu
George Y Wu
Original Assignee
Univ Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut filed Critical Univ Connecticut
Publication of MA41757A publication Critical patent/MA41757A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne, entre autres, des compositions et des trousses comprenant une asialoglycoprotéine liée de manière covalente à un polycation, et des mitochondries fonctionnelles de mammifère qui tirent au moins partiellement purifiées et sont électrostatiquement liées à la molécule de poly-asg; ainsi que des méthodes de préparation et d'utilisation.
MA041757A 2015-02-27 2016-02-26 Transplantation ciblée de mitochondries dans des hépatocytes MA41757A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126068P 2015-02-27 2015-02-27
PCT/US2016/019845 WO2016138420A1 (fr) 2015-02-27 2016-02-26 Transplantation ciblée de mitochondries dans des hépatocytes
US15/553,717 US10537594B2 (en) 2015-02-27 2016-02-26 Targeted transplantation of mitochondria to hepatocytes

Publications (1)

Publication Number Publication Date
MA41757A true MA41757A (fr) 2018-01-03

Family

ID=55587354

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041757A MA41757A (fr) 2015-02-27 2016-02-26 Transplantation ciblée de mitochondries dans des hépatocytes

Country Status (5)

Country Link
US (1) US10537594B2 (fr)
EP (1) EP3261677B1 (fr)
JP (1) JP2018507865A (fr)
MA (1) MA41757A (fr)
WO (1) WO2016138420A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
WO2019028469A1 (fr) * 2017-08-04 2019-02-07 The Methodist Hospital Compositions mitochondriales a polymère fonctionnalisé et procédés d'utilisation dans une transplantation cellulaire et pour modifier un phénotype métabolique
WO2019209051A1 (fr) * 2018-04-26 2019-10-31 주식회사 파이안바이오테크놀로지 Mitochondries modifiée et utilisation associée
AU2019311859B2 (en) 2018-07-22 2025-12-18 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
EP3823643A4 (fr) * 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. Thérapie d'augmentation mitochondriale de maladies hépatiques
WO2020021535A1 (fr) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Thérapie d'augmentation mitochondriale de maladies oculaires
EP3823646A4 (fr) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. Thérapie d'augmentation mitochondriale de maladies cérébrales
JP7586811B2 (ja) 2018-07-22 2024-11-19 ミノヴィア セラピューティクス リミテッド 腎臓疾患のミトコンドリア増強療法
EP3823644A4 (fr) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. Thérapie d'augmentation mitochondriale de maladies pancréatiques
US11951135B2 (en) 2018-07-22 2024-04-09 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
WO2020163856A1 (fr) * 2019-02-10 2020-08-13 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Mitochondrie modifiée et ses méthodes d'utilisation
BR112022019609A2 (pt) 2020-03-31 2022-11-29 Minovia Therapeutics Ltd Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas
TWI780431B (zh) * 2020-05-08 2022-10-11 台灣粒線體應用技術股份有限公司 新穎性醫藥組合物及其於修復肝臟損傷、治療肝臟損傷相關疾病與提升肝臟功能之用途
US20220354887A1 (en) * 2021-05-07 2022-11-10 University Of Connecticut Methods of preparing functional mitochondria and uses thereof
AU2023356237A1 (en) * 2022-10-06 2025-05-22 Mitrix Bio Inc. Formulations and methods for cellular therapies involving chimeric antigen receptors
WO2024167509A1 (fr) * 2023-02-10 2024-08-15 The Sallie Astor Burdine Breast Foundation Compositions et méthodes pour le traitement de lésions mitochondriales associées à un vol spatial

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5728399A (en) 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
TWI404801B (zh) * 2011-06-15 2013-08-11 胜肽粒線體移植系統方法及其用途
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
US8648034B2 (en) * 2011-12-09 2014-02-11 Changhua Christian Hospital Method and applications of peptide-mediated mitochondrial delivery system

Also Published As

Publication number Publication date
JP2018507865A (ja) 2018-03-22
WO2016138420A1 (fr) 2016-09-01
EP3261677B1 (fr) 2019-04-10
US10537594B2 (en) 2020-01-21
EP3261677A1 (fr) 2018-01-03
US20180036344A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
MA41757A (fr) Transplantation ciblée de mitochondries dans des hépatocytes
CL2025001077A1 (es) Métodos y composiciones para tolerancia a herbicidas ppo
CL2023000069A1 (es) Mezclas fungicidas
MA55131B1 (fr) Nouveaux composés hétérocycliques
CL2018000301A1 (es) Métodos y composiciones para tolerancia a los herbicidas en plantas
MA39803A (fr) Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation
MA46325B1 (fr) Composés dinucléotidiques cycliques
MA38248A1 (fr) Compositions pesticides et procédés associés
MA40671B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MX2020004578A (es) Composiciones de casz y metodos de uso.
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
MA39601A (fr) Composés 4,6-diamino-pyrido[3,2-d]pyrimidine modulateurs du récepteur de type toll
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
BR112015027327A2 (pt) composições e métodos para alterar a sinalização do mensageiro secundário
MA37572B1 (fr) Compositions pesticides et procédés correspondants
MX387529B (es) Nueva cepa de paenibacillus, compuestos antifungicos y metodos para su uso.
MA38143A1 (fr) Composition comprenant des agents de lutte biologique
MA38247A1 (fr) Compositions pesticides et procédés associés
EA200702680A1 (ru) Масляный суспензионный концентрат
MA38174A1 (fr) Souche de bifidobacterium animalis ssp. Animalis
MA42754A1 (fr) Résistance au virus tolcndv du melon
MX2020008125A (es) Composiciones que comprenden berberina.
MA46611A (fr) Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs
MA38526B1 (fr) Nouvelle souche bactérienne de lysobacter capsici et ses utilisations
EA201892500A1 (ru) Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции